# CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels

> **NCT03731169** · PHASE4 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 30 (actual)

## Conditions studied

- Aspergillosis Invasive
- Fungal Infection

## Interventions

- **GENETIC:** Voriconazole genotype-specific dosing
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT03731169
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-10
- **Primary completion:** 2019-08-31
- **Final completion:** 2020-08-28
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03731169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03731169, "CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03731169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*